Loading stock data…
Acrivon Therapeutics (ACRV)
$1.72+0.04 (+2.08%)
Market OpenUpdated 12:48 PM EDT
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acrivon Therapeutics, Inc. in the Healthcare sector is trading at $1.72 with a market capitalization of $64M. Wall Street consensus targets $11.50 (6 analysts), implying a +570.6% move over the next 12 months. The stock is currently 52% below its 52-week high of $3.56, remaining 7.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 78 is overbought against a weak tape. The Whystock Score of 5/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +570.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 78 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.90M↑ | -$20.12M↓ | -$19.69M↑ | -$22.65M↓ | -$21.66M |
| Net Income | -$19.04M↓ | -$18.98M↓ | -$18.23M↑ | -$21.01M↓ | -$19.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.90%
Volume
Today's trading volume
255,086
Recent News
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-
Penny Stocks To Watch In January 2026
As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares
Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?
Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.